Company profile

Novaremed AG

Novaremed is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain. Novaremed was founded in Israel in 2008, where development work was done up to a successful Phase IIa Proof of Concept (PoC) study in Diabetic Neuropathic Pain (DNP). In 2017, Novaremed moved from Israel to Basel, Switzerland, which is one of the most important biotech and pharma clusters in Europe. This relocation allowed the company to gain access to experienced clinical development staff and services and investor capital. Novaremed is currently preparing for a global Phase IIb study in DNP.

More news about Novaremed AG

25.07.2022 09:00

Novaremed receives USD 130 million in exclusive license agreement

Please login or
register to use the
awards follow feature
29.12.2021 15:40

Novaremed’s lead molecule enters Phase2b trials

Please login or
register to use the
awards follow feature
14.09.2021 14:32

Novaremed acquires Basel-based Metys Pharmaceuticals

Please login or
register to use the
awards follow feature
29.01.2021 15:37

Novaremed Secures US $50 Million

Please login or
register to use the
awards follow feature
21.09.2020 16:41

Novaremed raises CHF2.5 million and prepares Phase2b clinical study

Please login or
register to use the
awards follow feature
05.09.2019 16:11

Novaremed Secures CHF2.6 Million Additional Financing

Please login or
register to use the
awards follow feature
01.04.2019 16:45

Swiss Biotech Day to shed light on 13 emerging startups

Please login or
register to use the
awards follow feature
29.10.2018 08:50

Novaremed gets closer to ambition

Please login or
register to use the
awards follow feature
Novaremed AG

Founded
2008

Kanton
BS

Homepage

rss